Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 156 Records) |
| Query Trace: Neutropenia and UGT1A1[original query] |
|---|
| Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis. Bioscience reports 2020 Sep . Zhu Xiaoyun, Ma Ruchao, Ma Xin, Yang Ga |
| Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy. Scientific reports 2020 Aug 10 (1): 13486. Atasilp Chalirmporn, Chansriwong Phichai, Sirachainan Ekaphop, Reungwetwattana Thanyanan, Sirilerttrakul Suwannee, Chamnanphon Monpat, Puangpetch Apichaya, Sukasem Chonlaph |
| ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. Frontiers in pharmacology 2020 7 11 973. Riera Pau, Artigas-Baleri Alícia, Salazar Juliana, Sebio Ana, Virgili Anna C, Arranz María Jesús, Páez Dav |
| Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors. Pharmaceutical research 2020 Jul 37 (7): 147. Moeung Sotheara, Chevreau Christine, Marsili Sabrina, Massart Christophe, Fléchon Aude, Delva Rémy, Gravis Gwenaëlle, Lotz Jean-Pierre, Bay Jacques-Olivier, Gross-Goupil Marine, Filleron Thomas, Delmas Caroline, Lafont Thierry, Chatelut Etienne, Thomas Fabien |
| Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 10 38 (36): 4231-4239. Zhu Ji, Liu Anwen, Sun Xinchen, Liu Luying, Zhu Yaqun, Zhang Tao, Jia Jianhui, Tan Shisheng, Wu Junxin, Wang Xin, Zhou Juying, Yang Jialin, Zhang Chen, Zhang Hongyan, Zhao Yuanyuan, Cai Gang, Zhang Wei, Xia Fan, Wan Juefeng, Zhang Hui, Shen Lijun, Cai SanJun, Zhang Zh |
| UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers 2021 4 13 (7): . Nelson Ryan S, Seligson Nathan D, Bottiglieri Sal, Carballido Estrella, Cueto Alex Del, Imanirad Iman, Levine Richard, Parker Alexander S, Swain Sandra M, Tillman Emma M, Hicks J Kev |
| Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. CPT: pharmacometrics & systems pharmacology 2021 11 10 (12): 1550-1563. Brendel Karl, Bekaii-Saab Tanios, Boland Patrick M, Dayyani Farshid, Dean Andrew, Macarulla Teresa, Maxwell Fiona, Mody Kabir, Pedret-Dunn Anna, Wainberg Zev A, Zhang B |
| [Correlation between nUGT1A1 gene polymorphisms and adverse events of irinotecan plus S-1 for patients with recurrent or metastatic esophageal squamous cell carcinoma: a prospective, open-label, randomized controlled trial (ESWN 01)]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2021 11 43 (11): 1177-1182. Wang X, Liu Y, Huang J X, Lu P, Ba Y, Wu L, Bai Y X, Zhang S, Feng J F, Cheng Y, Li J, Wen L, Yuan X L, Ma C W, Hu C H, Fan Q X, Xu B H, Huang |
| DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols. British journal of clinical pharmacology 2021 Nov . Božina Nada, Bili? Ivan, Ganoci Lana, Šimi?evi? Livija, Pleština Stjepko, Lešnjakovi? Lucija, Trkulja Vladim |
| FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. Cancer chemotherapy and pharmacology 2021 Jan . Umemoto Kumiko, Takahashi Hideaki, Morizane Chigusa, Yamada Ikuhiro, Shimizu Satoshi, Shioji Kazuhiko, Yoshida Yukio, Motoya Masayo, Mizuno Nobumasa, Kojima Yasushi, Terashima Takeshi, Uesugi Kazuhiro, Ueno Makoto, Furuse Junji, Akimoto Tetsuo, Ikeda Masafu |
| Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer. Scientific reports 2022 9 12 (1): 15574. Irisawa Ai, Takeno Misaki, Watanabe Kazuo, Takahashi Hideaki, Mitsunaga Shuichi, Ikeda Masafu |
| Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 2022 Aug 8 (1): 98. Rugo Hope S, Tolaney Sara M, Loirat Delphine, Punie Kevin, Bardia Aditya, Hurvitz Sara A, O'Shaughnessy Joyce, Cortés Javier, Diéras Véronique, Carey Lisa A, Gianni Luca, Piccart Martine J, Loibl Sibylle, Goldenberg David M, Hong Quan, Olivo Martin, Itri Loretta M, Kalinsky Kev |
| Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis. Clinical and translational science 2022 May . Atasilp Chalirmporn, Biswas Mohitosh, Jinda Pimonpan, Nuntharadthanaphong Nutthan, Rachanakul Jiratha, Hongkaew Yaowaluck, Vanwong Natchaya, Saokaew Surasak, Sukasem Chonlaph |
| The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer. International journal of clinical oncology 2022 5 27 (8): 1331-1339. Satake Tomoyuki, Morizane Chigusa, Maruki Yuta, Ohba Akihiro, Nagashio Yoshikuni, Kondo Shunsuke, Hijioka Susumu, Ueno Hideki, Okusaka Taku |
| Characteristics and Clinical Implication of UGT1A1 Heterozygous Mutation in Tumor. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2022 3 25 (3): 137-146. Li Qian, Sun Tao, Zhang Hua, Liu Wei, Xiao Yu, Sun Hongqi, Yin Wencheng, Yao Yanhong, Gu Yangchun, Liu Yan'e, Yi Fumei, Wang Qiqi, Yu Jinyu, Cao Baoshan, Liang |
| Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma. Cancer medicine 2022 Mar . Imaya Masayuki, Muramatsu Hideki, Narita Atsushi, Yamamori Ayako, Wakamatsu Manabu, Yoshida Taro, Miwata Shunsuke, Narita Kotaro, Ichikawa Daisuke, Hamada Motoharu, Nishikawa Eri, Kawashima Nozomu, Nishio Nobuhiro, Kojima Seiji, Takahashi Yoshiyu |
| Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study. Cancers 2022 3 14 (5): . Keum Jiyoung, Lee Hee Seung, Jo Jung Hyun, Chung Moon Jae, Park Jeong Youp, Park Seung Woo, Song Si Young, Bang Seungm |
| Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study. Journal of personalized medicine 2022 2 12 (2): . Personeni Nicola, Giordano Laura, Michelini Angelica, D'Alessio Antonio, Cammarota Antonella, Bozzarelli Silvia, Pressiani Tiziana, Prete Maria Giuseppina, Sandri Maria Teresa, Stioui Sabine, Germagnoli Luca, Santoro Armando, Rimassa Lorenza, Mineri Rossa |
| The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan. ESMO open 2022 12 8 (1): 100746. Su Y-Y, Chiang N-J, Chang J S, Wang Y-W, Shen B-N, Li Y-J, Hwang D-Y, Shan Y-S, Chen L |
| Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan. European journal of human genetics : EJHG 2022 11 . Hulshof Emma C, Deenen Maarten J, Nijenhuis Marga, Soree Bianca, de Boer-Veger Nienke J, Buunk Anne-Marie, Houwink Elisa J F, Risselada Arne, Rongen Gerard A P J M, van Schaik Ron H N, Touw Daan J, van der Weide Jan, van Westrhenen Roos, Deneer Vera H M, Guchelaar Henk-Jan, Swen Jesse |
| Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity. Cancer medicine 2022 10 . Kanesada Kou, Tsunedomi Ryouichi, Hazama Shoichi, Ogihara Hiroyuki, Hamamoto Yoshihiko, Shindo Yoshitaro, Matsui Hiroto, Tokumitsu Yukio, Yoshida Shin, Iida Michihisa, Suzuki Nobuaki, Takeda Shigeru, Ioka Tatsuya, Nagano Hiroa |
| The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients. Genomics & informatics 2022 Sep 20 (3): e29. Lee Choong-Kun, Chon Hong Jae, Kwon Woo Sun, Ban Hyo-Jeong, Kim Sang Cheol, Kim Hyunwook, Jeung Hei-Cheul, Chung Jimyung, Rha Sun You |
| UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. European journal of cancer (Oxford, England : 1990) 2022 1 162 148-157. Hulshof Emma C, de With Mirjam, de Man Femke M, Creemers Geert-Jan, Deiman Birgit A L M, Swen Jesse J, Houterman Saskia, Koolen Stijn L W, Bins Sander, Thijs Anna M J, Laven Marjan M J, Hövels Anke M, Luelmo Saskia A C, Houtsma Danny, Shulman Katerina, McLeod Howard L, van Schaik Ron H N, Guchelaar Henk-Jan, Mathijssen Ron H J, Gelderblom Hans, Deenen Maarten |
| Predictive Value of ABCC2 and UGT1A1 Polymorphisms on Irinotecan-Related Toxicities in Patients with Cancer. Genetic testing and molecular biomarkers 2023 5 27 (5): 133-141. Zineb Aoullay, Andrew Smith, Meriem Slaoui, Ihssane El Bouchikhi, Hassan Ghazal, Najib Al Idrissi, Bouchra Meddah, Kara L Lynch, Yahia Cherrah, Alan H B |
| A single-center retrospective analysis of the efficacy and safety of a modified regimen of irinotecan plus S-1 (IRIS) with molecular targeting agents as second-line chemotherapy in Japanese patients with recurrent or nonresectable colorectal cancer. Journal of gastrointestinal oncology 2023 5 14 (2): 663-675. Shigeo Higami, Masaya Mukai, Daiki Yokoyama, Syuji Uda, Rin Abe, Nana Mamuro, Kyoko Kishima, Sayuri Hasegawa, Takayuki Tajima, Eiji Nomura, Hiroyasu Makuuc |
| Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101). Journal of clinical medicine 2023 2 12 (4): . Harada Kazuaki, Yamamura Takahiro, Muto Osamu, Nakamura Michio, Sogabe Susumu, Sawada Kentaro, Nakano Shintaro, Yagisawa Masataka, Muranaka Tetsuhito, Dazai Masayoshi, Tateyama Miki, Kobayashi Yoshimitsu, Kato Sosuke, Hatanaka Kazuteru, Kawamoto Yasuyuki, Yuki Satoshi, Sakata Yuh, Sakamoto Naoya, Komatsu Yoshi |
| A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC? Cancer chemotherapy and pharmacology 2023 11 . Angeline Ginzac, Emilie Thivat, Caroline Petorin, Damien Richard, Pauline Herviou, Ioana Molnar, Hervé Devaud, Isabelle Creveaux, Florent Ferrer, Nicolas Authier, Marine Jary, Denis Pezet, Xavier Duran |
| Meta-analysis revisiting the influence of UGT1A1*28 and UGT1A1*6 on irinotecan safety in colorectal cancer patients. Pharmacogenomics 2024 8 1-10. Cuc Thi Thu Nguyen, Nguyen Thi Minh Thuy, Phung Thanh Huo |
| Risk Factors for Adverse Events of Nanoliposomal Irinotecan Plus 5-Fluorouracil and L-leucovorin. Cancer diagnosis & prognosis 2024 5 4 (3): 244-249. Takahiro Ito, Manabu Suno, Hideki Egawa, Serina Hiraoka, Kohei Kamei, Shohei Sano, Reiko Ashida, Manabu Kawai, Kazuo Matsuba |
| Assessing the Occurrence and Influence of Cancer Chemotherapy-Related Pharmacogenetic Alleles in the Chilean Population. Pharmaceutics 2024 4 16 (4): . Gareth I Owen, Miguel Cordova-Delgado, Bernabé I Bustos, Leslie C Cerpa, Pamela Gonzalez, Sebastián Morales-Pison, Benjamín Garcia-Bloj, Marcelo Garrido, Juan Francisco Miquel, Luis A Quiñon |
- Page last reviewed:Feb 1, 2024
- Content source: